Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201.
OBJECTIVE
We previously reported the feasibility of short-term low-volume hydration in patients with advanced lung cancer who received cisplatin-based chemotherapy (Jpn J Clin Oncol 2013). We sought to determine the clinical usefulness of a more convenient hydration method, evaluating the safety and efficacy of shorter-term and lower-volume hydration.


METHOD
Chemonaïve patients with advanced lung cancer who were ≤ 75 years and reserved an adequate renal function for cisplatin use (≥ 60 mg/m(2)) were eligible. An intravenously administered hydration of 1700 ml in ~3.5 h with 1500 ml of orally administered hydration was investigated. The primary endpoint was the proportion of patients without grade 2 or worse renal toxicity in the first cycle.


RESULTS
A total of 45 patients were registered, all of whom were evaluable for renal toxicity. The median baseline creatinine score was 0.70 mg/dl, and the median cisplatin dose on day 1 was 75 mg/m(2). In the first cycle, one patient (2 %) developed grade 2 creatinine toxicity, and thus, the proportion of patients with less than grade 2 was 98 % (the lower limit of 95 % confidence interval; 93 %), which met the primary endpoint. Five patients (11 %) had grade 1 or greater nephrotoxicity, three of whom successfully recovered. The objective response rate was 24 % and median progression-free survival 5.8 months.


CONCLUSION
This prospective study demonstrated the safety and efficacy of shorter-term lower-volume hydration.
['Ninomiya|Kiichiro|K|', 'Hotta|Katsuyuki|K|', 'Hisamoto-Sato|Akiko|A|', 'Ichihara|Eiki|E|', 'Gotoda|Hiroko|H|', 'Morichika|Daisuke|D|', 'Tamura|Tomoki|T|', 'Kayatani|Hiroe|H|', 'Minami|Daisuke|D|', 'Kubo|Toshio|T|', 'Tabata|Masahiro|M|', 'Tanimoto|Mitsune|M|', 'Kiura|Katsuyuki|K|']
D058186:Acute Kidney Injury D000328:Adult D000368:Aged D000971:Antineoplastic Combined Chemotherapy Protocols D002945:Cisplatin D003404:Creatinine D018572:Disease-Free Survival D005240:Feasibility Studies D005260:Female D005440:Fluid Therapy D006801:Humans D007564:Japan D008175:Lung Neoplasms D008297:Male D008875:Middle Aged D011446:Prospective Studies D066066:Response Evaluation Criteria in Solid Tumors
Hydration Lung cancer Cisplatin